Takeda Pharmaceutical (TAK) EBITDA Margin (2018 - 2026)
Takeda Pharmaceutical (TAK) reported EBITDA Margin of 29.88% for the quarter ended Jun 30, 2026, down 3.21 percentage points from 33.09% a year earlier and down 2.45 percentage points from the prior quarter.
Takeda Pharmaceutical (TAK) EBITDA Margin (2018 - 2026) Analysis & Trends
Over the twelve months ended Jun 30, 2026, Takeda Pharmaceutical's EBITDA Margin came in at 22.86%, down 5.82 percentage points year-over-year; for the year ended Mar 31, 2026, it was 16.14%, down 7.95 percentage points from the prior year.
- EBITDA Margin has a five-year change of -17.28 percentage points (years ended Mar 2021 to Mar 2026).
- By year, EBITDA Margin came in at 24.10% in the year ended Mar 31, 2025 (+2.00 pp), 22.09% in the year ended Mar 31, 2024 (-6.58 pp), 28.68% in the year ended Mar 31, 2023 (-0.58 pp) and 29.25% in the year ended Mar 31, 2022 (-4.18 pp).
- Five-year quarterly EBITDA Margin spans a low of -20.61% in the quarter ended Dec 31, 2025 and a high of 64.79% in the quarter ended Sep 30, 2022.
- Year over year, EBITDA Margin has now declined in each of the last four quarters, with an average year-over-year change of -6.18 percentage points over the last eight quarters.
- The high point for year-over-year EBITDA Margin in five years was the quarter ended Jun 30, 2025 (a gain of 3.41 percentage points); the low point was the quarter ended Sep 30, 2023 (a drop of 31.26 percentage points).
- Per Business Quant data, the three quarters before the quarter ended Jun 30, 2026 came in at 32.33% (quarter ended Mar 31, 2026), -20.61% (quarter ended Dec 31, 2025) and 30.45% (quarter ended Sep 30, 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,156.72 Bn | 1,125.31 Bn | 19.71 Bn | 53.49% |
| 2 | Johnson & Johnson | 623.54 Bn | 542.07 Bn | 17.26 Bn | 35.95% |
| 3 | AbbVie | 513.03 Bn | 486.14 Bn | 12.70 Bn | 49.01% |
| 4 | Merck | 365.42 Bn | 319.80 Bn | 12.21 Bn | 6.02% |
| 5 | Novartis Ag | 297.47 Bn | 261.46 Bn | 11.24 Bn | - |
| 6 | Astrazeneca | 261.54 Bn | 235.23 Bn | 12.86 Bn | 33.11% |
| 7 | Amgen | 235.13 Bn | 190.53 Bn | 7.24 Bn | 46.01% |
| 8 | Gilead Sciences | 193.32 Bn | 167.51 Bn | 6.22 Bn | -124.26% |
| 9 | Pfizer | 171.63 Bn | 118.28 Bn | 10.94 Bn | 39.16% |
| 10 | Takeda Pharmaceutical | 63.13 Bn | 39.49 Bn | 5.10 Bn | 29.88% |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 29.88% |
| Mar 31, 2026 | 29.94% |
| Dec 31, 2025 | -20.61% |
| Sep 30, 2025 | 17.22% |
| Jun 30, 2025 | 33.09% |
| Mar 31, 2025 | 30.99% |
| Dec 31, 2024 | 10.64% |
| Sep 30, 2024 | 17.29% |
| Jun 30, 2024 | 29.68% |
| Mar 31, 2024 | 29.42% |
| Dec 31, 2023 | 26.23% |
| Sep 30, 2023 | 18.20% |
| Jun 30, 2023 | 32.12% |
| Mar 31, 2023 | 31.17% |
| Dec 31, 2022 | 29.54% |
| Sep 30, 2022 | 27.16% |
| Jun 30, 2022 | 31.75% |
| Mar 31, 2022 | 41.22% |
| Jun 30, 2021 | 41.23% |
| Mar 31, 2021 | 50.36% |
Takeda Pharmaceutical EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=TAK&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "TAK", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=TAK&period=max&api_key=YOUR_API_KEY");
const data = await res.json();